Accreditation Statistics

As of August 1, 2022

Cellular Therapy Entities

  • Accredited: 250
  • Applicants: 25

Cord Blood Banks

  • Accredited: 56
  • Applicants: 7

Congratulations to the following program for achieving initial FACT accreditation: King Abdulaziz Medical City - Riyadh, Saudi Arabia (adult and pediatric allogeneic and autologous hematopoietic progenitor cellular therapy; marrow and peripheral blood cellular therapy product collection; cellular therapy product processing with minimal manipulation). A complete list of accredited organizations can be found at www.factwebsite.org.

FDA Releases Suggestions for Evaluating Donors for Coronavirus

Posted in :: 2020 Volume 2 :: Monday, March 16th, 2020

The United States Food and Drug Administration (FDA) published Important Information for Human Cell, Tissue, or Cellular or Tissue-based Product (HCT/P) Establishments Regarding the 2019 Novel Coronavirus Outbreak on February 14, 2020. This announcement notes that the FDA has been working closely with the Center for Disease Control (CDC) and other federal and international agencies to monitor the outbreak of coronavirus (COVID-19).

The FDA stated that respiratory viruses are not generally known to be transmitted by HCT/Ps, potential for coronavirus transmission via these products is unknown. Although routine screening measures for infections are already in use, some programs may wish to use additional donor screening in response to this outbreak.  Based on limited information available, the FDA says programs may wish to consider the donor history in the 28 days prior to cell collection for potential donors who have:

  • traveled to areas with COVID-19 outbreaks, as defined by CDC
  • lived with individuals diagnosed with or suspected of having COVID-19 infection; or
  • been diagnosed with or suspected of having COVID-19 infection.

The following are additional details provided by FDA: